Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIM101
- Development stage
- Unknown
- Lead developer
- CiMaas
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CIM101 is an ex vivo expanded and activated natural killer (NK) cell therapy being developed by CiMaas for the treatment of acute myeloid leukemia (AML). The therapy can be produced from either autologous (patient-derived) or allogeneic (donor-derived) sources. CIM101 is manufactured using a proprietary expansion technology that utilizes a unique feeder cell line expressing membrane-bound interleukin-21 (IL-21) and 4-1BB ligand (4-1BBL), which stimulates the rapid proliferation and activation of highly cytotoxic NK cells. These expanded cells are designed to recognize and eliminate leukemic blasts through a repertoire of natural activating receptors, including NKG2D and natural cytotoxicity receptors (NCRs), which trigger the release of perforin and granzymes to induce tumor cell apoptosis. CIM101 is currently being evaluated in Phase 1 clinical trials to assess its safety and feasibility in patients with relapsed or refractory AML.
- Other names
- CiMaas NK cell therapy
Beyond the preview
Go deeper on CIM101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIM101.